segunda-feira, 7 de setembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 26, 2026

Conflux Capital launches mobile app, supporting one-click arbitrage of BTC, ETH, XRP, and DOGE

View original at globenewswire.com
Conflux Capital launches mobile app, supporting one-click arbitrage of BTC, ETH, XRP, and DOGE LONDON, March 26, 2026 (GLOBE NEWSWIRE) -- To address the latest record, Conflux Capital launches a mobile app that will support one-click arbitrage of BTC, ETH, XRP, and DOGE…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The mobile app ensures uninterrupted returns 24/7

    60% confidence

  • The platform system is 100% operational, meeting user investment needs and providing 24/7 technical support

    60% confidence

  • The platform hopes to promote the popularization of cryptocurrency quantitative arbitrage by lowering the operational threshold, allowing more people to participate conveniently

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,981
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,981 factos verificados com a fonte5,273 documentos-fonte arquivados
Consulte estes dados → isubstrate.com